Home' Australian Pharmacist : Australian Pharmacist May 2012 Contents 406 Australian Pharmacist May 2012 I ©Pharmaceutical Society of Australia Ltd.
Continuing Professional Development
The articles in this series are independently researched and compiled by PSA commissioned authors and peer reviewed.
Submit your answers online before
1 July 2012 at www.psa.org.au
and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA's
CPD&PI program. It is also part of the New Zealand
College of Pharmacists (NZCP) education program
for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4
out of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD Credits.
If not submitting online, write the correct answers
in the spaces provided on the answer panel on
the back of the address sheet, ll in your name,
member number and address details, then either
mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
1. Which of the following statements is
a) Mood stabilisers are medications
which are indicated speci cally for the
depressive phase of bipolar disorder.
b) The use of antidepressants in bipolar is
associated with increased risk of switch
to mania or hypomania as outlined in
the STEP-BD study.
c) Clinical features of mania include
somnolence, ight ideas, increased
activity and sexual drive.
d) Manic relapses in established bipolar
disorder are often the result of poor
2. Which of the following is NOT an
adverse e ect associated with the
use of sertraline therapy?
a) Increased sex drive.
b) Weight gain.
3. Which of the following routine
investigations is NOT recommended
following a TIA for individuals who
are not taking warfarin and who
have no established risk factors?
d) ELFTs and renal function.
4. Which of the following medications
regimes is recommended following
a) Clopidogrel, atenelol and
b) Aspirin, atorvastatin and perindopril.
c) Feno brate, telmisartan and aspirin.
d) Clopidogrel, perindopril and
5. Which of the following statements
is LEAST accurate?
a) Following a TIA the use of
ACE inhibitors +/- a diuretic is
recommended for BP management.
b) Statin use should only be administered
following a TIA after lipid studies have
ascertained necessity of use.
c) A diet low in saturated fats and high in
omega 3 and 6 fatty acids helps prevent
increased risk of CVD and stroke.
d) Elevated BP, age > 60 and diabetes are
all risk factors which are indicative of a
stroke following a TIA.
A score of 4 out of 5 attracts 1 CPD credits.
1. eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines;
Psychotropic; Mood disorders; bipolar disorder; general
2. PubMed health at: www.ncbi.nlm.nih.gov/pubmedhealth/
3. Effectiveness of adjunctive antidepressant treatment for
bipolar depression. The New England Journal of Medicine.
Apr 26, 2007;356:17. At: www.nejm.org/doi/full/10.1056/
4. Questions and answers about STEP-BD acute depression
medication trial. At: www.nimh.nih.gov/trials/practical/
5. Systematic treatment enhancing program for bipolar
6. Calabrese JR, Rapport DJ. Mood stabilizers and the evolution
of maintenance study designs in bipolar I disorder. J Clin
Psychiatry 1999;60(suppl 5): 5--13. As found at: http://
7. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin
North Am 1996;19:215--236. As found at: http://altcancerweb.
8. eMIMS. [CD] In: 5.0 ed. Sydney: MediMedia Australia; Dec 2010.
9. Consensus on antithrombotic medicines. Best Practice Journal.
Oct 2011;39. At: www.bpac.org.nz/magazine/2011/october/
10. Medscape Medical News: Early, aggressive treatment of TIA
dramatically reduces recurrent stroke risk at: www.medscape.
11. eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines;
12. Mayo Clinic. Heart disease. Heart healthy diet, 8 steps to
prevent heart disease at: www.mayoclinic.com/health/heart-
13. Heart healthy diet tips: eating to prevent heart disease and
boost heart health at: http://helpguide.org/life/healthy_diet_
14. Rossi S, ed. Australian Medicines Handbook. Adelaide:
Australian Medicines Handbook; 2012;776--8
15. eTG complete [CD-ROM]. Melbourne: Therapeutic Guidelines;
Psychotropic; Mood disorders; bipolar disorder; prophylaxis for
bipolar disorder: pharmacological treatment.
16. Using antithrombotics wisely in stroke prevention. NPS
News, Feb 2009. At: www.nps.org.au/health_professionals/
17. Medscape. Stroke prevention. At: http://emedicine.medscape.
18. Medscape. Statins should be part of preventative
management in stroke prevention. At: http://www.medscape.
19. Advances in stroke 2002. Angiotensin-Converting Enzyme
inhibitors for stroke prevention. At: http://stroke.ahajournals.
20. Medscape Pharmacist. Weiner Hacke. ACE inhibitors and
secondary TIA prevention. At: http://www.medscape.com/
Links Archive Australian Pharmacist June 2012 Australian Pharmacist April 2012 Navigation Previous Page Next Page